A Multiplexed RF-QTOF MS & Genedata Platform for Covalent Ligand Discovery

The discovery of covalent inhibitors has become a powerful strategy in drug development due to their ability to form irreversible bonds with target proteins, resulting in enhanced therapeutic indices. While high-throughput screening (HTS) assays are widely used to evaluate large compound libraries, differentiating true hits from false positives remains a significant challenge. To address this, mass spectrometry (MS)-based techniques are increasingly being integrated into screening workflows to directly assess target engagement. However, despite their advantages, MS workflows have traditionally been limited by low throughput data acquisition and processing, hindering their application in early-stage hit discovery.

In this webinar, learn how Pfizer and Genedata partnered in the development of a fast and robust high-throughput mass spectrometry (HT-MS) assay that accelerates covalent ligand discovery in biopharmaceutical R&D. By integrating the Agilent RapidFire (RF) system with a quadrupole time-of-flight (QTOF) mass spectrometer and the Genedata Biopharma Platform, Pfizer established a robust workflow for rapid and multiplexed detection of covalent interactions between small-molecule inhibitors and target proteins.

Learn how this innovative platform enables:

Discovery of novel and selective CDK-Cyclin covalent inhibitors/modifiers.
Multiplexed detection of distinct functional readouts to differentiate mechanisms of action within a single data set.
Screening of over 2,000 label-free compounds per day using Genedata Expressionist and Genedata Screener, significantly accelerating early-stage covalent ligand discovery.

Who should watch:

R&D Managers, Analytical Scientists, and Lab Heads in Biopharma, Biotech, and CROs seeking to implement automated HT-MS screening workflows.
Organizations looking to adopt an enterprise platform to streamline MS analytics across discovery, research, development, and screening labs.